Risperidone and Circulatory collapse - a phase IV clinical study of FDA data

Summary:

Circulatory collapse is reported as a side effect among people who take Risperidone (risperidone), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Amlodipine, and have High blood pressure.

The phase IV clinical study analyzes which people have Circulatory collapse when taking Risperidone. It is created by eHealthMe based on reports of 70,786 people who have side effects when taking Risperidone from the FDA, and is updated regularly.

What is Risperidone?

Risperidone has active ingredients of risperidone. It is often used in bipolar disorder. eHealthMe is studying from 72,175 Risperidone users. Check the latest studies of Risperidone.

What is Circulatory collapse?

Circulatory collapse is found to be associated with 1,122 drugs and 1,402 conditions by eHealthMe. Check the latest studies of Circulatory collapse.

On Jul, 17, 2026

70,786 people reported to have side effects when taking Risperidone.
Among them, 146 people (0.21%) have Circulatory collapse.

Could Risperidone cause Circulatory collapse?

Among these 146 people:

How long have people been on Risperidone when they have Circulatory collapse? *

Click here to view more results

What is the gender of people who have Circulatory collapse when taking Risperidone? *

Click here to view

What is the age of people who have Circulatory collapse when taking Risperidone? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Risperidone and have Circulatory collapse?

- Check whether Circulatory collapse is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Risperidone:

Risperidone (72,175 reports)

Circulatory collapse treatments and more:

Circulatory collapse (21,467 reports)

How severe was Circulatory collapse and when was it recovered:

Circulatory collapse in Risperidone

Expand to all the drugs that have ingredients of risperidone:

Circulatory collapse and drugs with ingredients of risperidone (291 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Risperidone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Circulatory collapse:

Circulatory collapse (1,122 drugs)

Browse all the conditions that are associated with Circulatory collapse:

Circulatory collapse (1,402 conditions)

Related publications that referenced our studies

Janardhana P, Nagaraj AK, Basavanna PL, "Risperidone-induced skin rash", Indian journal of psychiatry, 2016 Jan .
Dsouza MC, "Could risperidone have caused the cataract?: A case report and review of literature", Journal of Research in Psychiatry and Behavioral Science, 2015 Jan .
Dsouza MC, "COULD RISPERIDONE HAVE CAUSED THE CATARACT", JRPBS, 2015 Jan .
Ray RK, Bashir MA, Rao S, "Co-Administration of Risperidone and Sodium Valproate Causing Bilateral Chronic Exertional Lower Leg Compartment Syndrome", Open Journal of Orthopedics, 2014 Apr .
Hosseini, S. H., & Ahmadi, A., "Peripheral edema occurring during treatment with risperidone combined with citalopram", Case reports in medicine, 2012 Jan .
Janardhana P, Nagaraj AK, Basavanna PL, "Risperidone-induced skin rash", Indian journal of psychiatry, 2016 Jan .
Dsouza MC, "Could risperidone have caused the cataract?: A case report and review of literature", Journal of Research in Psychiatry and Behavioral Science, 2015 Jan .
Dsouza MC, "COULD RISPERIDONE HAVE CAUSED THE CATARACT", JRPBS, 2015 Jan .
Ray RK, Bashir MA, Rao S, "Co-Administration of Risperidone and Sodium Valproate Causing Bilateral Chronic Exertional Lower Leg Compartment Syndrome", Open Journal of Orthopedics, 2014 Apr .
Hosseini, S. H., & Ahmadi, A., "Peripheral edema occurring during treatment with risperidone combined with citalopram", Case reports in medicine, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on risperidone (the active ingredients of Risperidone) and Risperidone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.